Pomerantz To Rep Investors In Acadia Drug Deaths Case

Law360 (February 27, 2019, 5:17 PM EST) -- Pomerantz LLP has been appointed as lead counsel in a proposed securities fraud class action alleging Acadia Pharmaceuticals Inc. inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its flagship drug used to treat hallucinations and delusions, Nuplazid.

U.S. District Court Judge Anthony Battaglia, who also on Tuesday granted shareholder Thomas Wood’s motion to be lead plaintiff in the California federal court case, said Pomerantz has represented investors in many securities fraud causes.

“The court finds Pomerantz has the resources and experience to effectively manage the class litigation,” the judge wrote.

Judge Battaglia also found...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

California Southern

Nature of Suit

Securities/Commodities

Judge

Subscribers Only

Date Filed

July 19, 2018

Law Firms

Companies

Government Agencies

Judge Analytics